

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1492	546/208;548/374.1.ccls.	USPAT	OR	ON	2006/10/23 13:11
L2	149	l1 and pyrazol	USPAT	OR	ON	2006/10/23 13:11
L3	115	l2 and pharmaceut\$	USPAT	OR	ON	2006/10/23 13:25
L4	1	dow-robert.in.	USPAT	OR	ON	2006/10/23 13:20
L5	23	hammond-marlys.in.	USPAT	OR	ON	2006/10/23 13:21
S1	35	("20010027193" "20010053788" "20020019383" "20020019421" "20020035102" "20020091114" "20020128302" "20020188007" "20030003145" "20030055033" "20030139386" "20030199536" "20040077650" "20040092520" "4925846" "4944790" "5134142" "5462960" "5596106" "5624941" "5744491" "5744493" "5747524" "5925768" "6028084" "6100259" "6344474" "6355631" "6432984" "6476060" "6479479" "6509367" "6518264" "6531492" "6566356").PN.	US-PGPUB; USPAT	OR	ON	2006/10/23 12:57
S2	0	wo-2002053565-\$.did.	USPAT; DERWENT	OR	ON	2006/10/23 11:47
S3	1	wo-200253565-\$.did.	USPAT; DERWENT	OR	ON	2006/10/23 11:47
S4	1	wo-2004077650-\$.did.	USPAT; DERWENT	OR	ON	2006/10/23 11:49
S5	0	2004077650-\$.did.	US-PGPUB; USPAT; DERWENT	OR	ON	2006/10/23 11:49
S6	0	"2004077650.9n."	US-PGPUB; USPAT; DERWENT	OR	ON	2006/10/23 11:49
S7	0	"20040077650.9n."	US-PGPUB; USPAT; DERWENT	OR	ON	2006/10/23 11:49
S8	0	"20040077650.pn."	US-PGPUB; USPAT; DERWENT	OR	ON	2006/10/23 11:49
S9	0	"2004077650.pn."	US-PGPUB; USPAT; DERWENT	OR	ON	2006/10/23 11:50
S10	0	"20040077650.pn."	US-PGPUB; USPAT; DERWENT	OR	ON	2006/10/23 11:50
S11	0	"200477650.pn."	US-PGPUB; USPAT; DERWENT	OR	ON	2006/10/23 11:50

Andrew Freistein 10/702,149

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptabf1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right
truncation
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme
NEWS 12 OCT 18 The Derwent World Patents Index suite of databases on STN will
be enhanced and reloaded on October 22, 2006

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:30:53 ON 18 OCT 2006

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:31:09 ON 18 OCT 2006

Andrew Freistein 10/702,149

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 OCT 2006 HIGHEST RN 910609-94-8
DICTIONARY FILE UPDATES: 17 OCT 2006 HIGHEST RN 910609-94-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10702149\b.str



```

chain nodes :
8 14 15 16 20 21 22 23 24 25 30
ring nodes :
1 2 3 4 5 9 10 11 12 13
chain bonds :
1-22 3-8 10-24 12-14 15-16 15-20 20-21 20-30 22-23 24-25
ring bonds :
1-2 1-5 2-3 3-4 4-5 9-10 9-13 10-11 11-12 12-13
exact/norm bonds :
1-2 1-5 1-22 2-3 3-4 3-8 4-5 9-10 9-13 10-11 11-12 12-13 12-14 15-16
20-21 20-30 22-23 24-25
exact bonds :
10-24 15-20

```

G2:H,X,Ak,CN

G3:[*1],[*2]

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 8:CLASS 9:Atom 10:Atom 11:Atom 12:Atom
13:Atom 14:CLASS 15:CLASS 16:CLASS 20:CLASS 21:CLASS 22:CLASS 23:Atom
24:CLASS 25:Atom 30:CLASS

```

Andrew Freistein 10/702,149

Generic attributes :

23:

Saturation : Unsaturated

25:


Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1

G2 H, X, Ak, CN

G3 [01], [02]

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:31:34 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 174 TO ITERATE

100.0% PROCESSED 174 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2689 TO 4271

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 16:31:38 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3286 TO ITERATE

10/23/2006

Page 4

Andrew Freistein 10/702,149

100.0% PROCESSED 3286 ITERATIONS
SEARCH TIME: 00.00.01

23 ANSWERS

L3 23 SEA SSS FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'HCAPLUS' ENTERED AT 16:31:41 ON 18 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Oct 2006 VOL 145 ISS 17

FILE LAST UPDATED: 17 Oct 2006 (20061017/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 5 L3

=> d ibib abs hitstr 1-5

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:547243 HCAPLUS

DOCUMENT NUMBER: 143:78189

TITLE: Preparation of heterocyclyl substituted alkoxyacetic acid amides as inhibitors of formation of coagulation factors Xa, IXa, and thrombin

INVENTOR(S): Gobbi, Luca Claudio; Zbinden, Katrin Groebke; Mohr, Peter; Obst, Ulrike

PATENT ASSIGNEE(S): Hoffman-La Roche Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 32 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2005137168	A1	20050623	US 2004-9464	20041210
US 7056932	B2	20060606		

AU 2004299243	A1	20050630	AU 2004-299243	20041213
CA 2549825	AA	20050630	CA 2004-2549825	20041213
WO 2005058868	A1	20050630	WO 2004-EP14185	20041213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1706396	A1	20061004	EP 2004-803815	20041213
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

PRIORITY APPLN. INFO.: EP 2003-104822 A 20031219
WO 2004-EP14185 W 20041213

OTHER SOURCE(S): MARPAT 143:78189
GI



AB The invention is concerned with novel heterocyclyl substituted 1-alkoxy acetic acid derivs. of formula (I) [wherein A = (un)substituted heterocyclyl such as pyrazolyl, triazolyl, 1-oxo-1,3-dihydroisoindolyl, 1,3-dioxo-1,3-dihydroisoindolyl, oxazolyl, benzimidazolyl, 1,2,4-oxadiazol-5-yl and 2-oxo-2H-pyridinyl; R1 = C1-7 alkyl; R2 = H, C1-7 alkyl; R3, R4, R5 = C1-7 alkyl-NH, H, halogen, carbamoyl-C1-7 alkoxy, carboxy-C1-7 alkoxy, carboxy-C1-7 alkyl-NH, C1-7 alkoxy-CO-C1-7 alkoxy, C1-7 alkoxy-CO-C1-7 alkyl-NH, carbamoyl-C1-7 alkyl-NH, C1-7 alkyl-NH-CO-C1-7 alkoxy, C1-7 alkyl-NH-CO-C1-7 alkyl-NH, aryl-NH-CO-C1-7 alkoxy, aryl-NH-CO-C1-7 alkyl-NH, carboxy-C1-7 alkyl-NH-CO-C1-7 alkoxy, carboxy-C1-7 alkyl-NH-CO-C1-7 alkyl-NH, C1-7 alkoxy-CO-C1-7 alkyl-NH-CO-C1-7 alkoxy, C1-7 alkoxy-CO-C1-7 alkyl-NH-CO-C1-7 alkyl-NH, aryloxy, aryl-NH, aryl-NH-CO-NH, aryl-O-CO-NH, aryl-C1-7 alkoxy, aryl-C1-7 alkyl-NH, aryl-C1-7 alkyl-NH-CO-NH, aryl-C1-7 alkoxy-CO-NH, heteroaryloxy, heteroaryl-NH, heteroaryl-NH-CO-NH, heteroaryl-O-CO-NH, heteroaryl-C1-7 alkoxy, heteroaryl-C1-7 alkyl-NH, heteroaryl-C1-7 alkyl-NH-CO-NH, heteroaryl-C1-7 alkoxy-CO-NH, aryl-CO-NH, heteroaryl-CO-NH, etc.; R6 = H, HO, aryl-C1-7 alkoxy-carbonyl, aryl-carbonyl, aryloxy-carbonyl; or R5 and R6 are bound together to form a ring; or R5-R6 = O, NH] and pharmaceutically acceptable salts thereof. These compds. inhibit the formation of coagulation factors Xa, IXa and thrombin induced by factor VIIa and tissue factor and can be used as medicaments for the therapeutic and/or prophylactic treatment of arterial and venous thrombosis, deep vein thrombosis, pulmonary embolism, unstable angina pectoris, cardiac infarction and stroke due to atrial fibrillation, inflammation, arteriosclerosis, and/or tumor. For example, (RS)-N-(4-

carbamimidoylbenzyl)-2-[3-(5-chloro-2-hydroxyphenyl)pyrazol-1-yl]-2-ethoxyacetamide hydrochloride and (RS)-N-(4-carbamimidoylbenzyl)-2-ethoxy-2-[2-oxo-3-[(phenylmethylsulfonyl)amino]-2H-pyridin-1-yl]acetamide acetate showed K_i of 0.76 and 0.43 μM , resp., in the prothrombin time (PT) clotting test using human plasma.


IT 854761-56-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclyl substituted 1-alkoxy acetic acid amides as inhibitors of formation of coagulation factors Xa, IXa, and thrombin)

RN 854761-56-1 HCAPLUS

CN 1H-Pyrazole-3-acetamide, N-[[4-(aminoiminomethyl)phenyl]methyl]- α -methoxy-1-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:160837 HCAPLUS

DOCUMENT NUMBER: 142:233372

TITLE: Pharmaceutical composition using a combination of an opioid receptor antagonist and a CB-1 receptor antagonist for the prevention and treatment of addiction in a mammal

INVENTOR(S): Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford

PATENT ASSIGNEE(S): Pfizer Inc, USA

SOURCE: U.S. Pat. Appl. Publ., 25 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043327	A1	20050224	US 2004-870209	20040617
CA 2536280	AA	20050303	CA 2004-2536280	20040809
WO 2005018645	A1	20050303	WO 2004-IB2596	20040809

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1658082 A1 20060524 EP 2004-744231 20040809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: US 2003-496803P P 20030821
WO 2004-IB2596 W 20040809


AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

IT 709033-30-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

RN 709033-30-7 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl- α -[[[(1-methylethyl)(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:902356 HCAPLUS

DOCUMENT NUMBER: 141:379921

TITLE: Biaryl-substituted pyrazoles as sodium channel blockers, and their preparation, pharmaceutical compositions, and use in the treatment of pain

INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Tyagarajan, Sriram; Zhou, Bishan

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092140	A1	20041028	WO 2004-US9713	20040330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004230854	A1	20041028	AU 2004-230854	20040330
CA 2520804	AA	20041028	CA 2004-2520804	20040330
EP 1615895	A1	20060118	EP 2004-759062	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1798738	A	20060705	CN 2004-80014916	20040330
JP 2006522130	T2	20060928	JP 2006-509477	20040330
US 2006183785	A1	20060817	US 2005-552024	20051003
PRIORITY APPLN. INFO.:			US 2003-460106P	P 20030403
			WO 2004-US9713	W 20040330
OTHER SOURCE(S):	MARPAT 141:379921			
GI				



AB Biaryl-substituted pyrazole compds., which are sodium channel blockers, useful for the treatment of pain and other conditions, are disclosed. The compds. generally conform to the structure Ar1-Ar2-Ar3 [I; Ar1 = Ph with 0-3 selected substituents, typically H, Cl, CF3, OCF3, etc.; Ar2 = 1,3-phenylene, 3,5-, 2,4-, 2,6-, or 4,2-pyridinediyl, or 2,6-pyrazinediyl, all with 0-2 selected substituents, typically H, F, OCF3; Ar3 = pyrazol-1-yl or pyrazol-3(5)-yl, with 0-3 selected substituents, typically H, CO2H, CONH2, CO2Me, CO2Et, Me, etc.; including pharmaceutically acceptable salts]. Pharmaceutical compns. comprise an effective amount of I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treatment of conditions, including acute pain, chronic pain, visceral pain, inflammatory pain, and neuropathic pain, comprise administering an effective amount of I, either alone, or in combination with one or more therapeutically active compds. I displayed sodium channel blocking activity at concns. ranging from about <0.1 μ M to about <50 μ M in several described in vitro assays, e.g., in an electrophysiol. assay using an HEK-293 cell line stably expressing the PN1 sodium channel subtype. Approx 300 specific invention compds. were prepared and listed individually in examples and/or claims. Several preps. are described in detail. For instance, invention compound II was prep'd in 4 steps. Thus, cyclocondensation of 3-BrC6H4NHNH2.HCl with Et 2,4-dioxovalerate in

refluxing AcOH gave 84% Et 1-(3-bromophenyl)-5-methyl-1H-pyrazole-3-carboxylate. Alkaline hydrolysis of this ester with 2N NaOH gave 89% of the corresponding acid, which was activated with 1,1-carbonyldiimidazole and amidated with NH4OAc to give 82% 1-(3-bromophenyl)-5-methyl-1H-pyrazole-3-carboxamide. Suzuki coupling of this bromide with 2-CF3OC6H4B(OH)2 (preparation given) gave 88% II.

IT 784141-47-5P, 2-Hydroxy-2-[5-methyl-1-[2'-(trifluoromethoxy)-1,1'-biphenyl-3-yl]-1H-pyrazol-3-yl]acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of biaryl-substituted pyrazoles as sodium channel blockers, particularly as analgesics)
 RN 784141-47-5 HCAPLUS
 CN 1H-Pyrazole-3-acetamide, α -hydroxy-5-methyl-1-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:515489 HCAPLUS
 DOCUMENT NUMBER: 141:54345
 TITLE: Preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor antagonists.
 INVENTOR(S): Dow, Robert Lee; Hammond, Marlys
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052864	A1	20040624	WO 2003-IB5835	20031203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004122074	A1	20040624	US 2003-702149	20031104
CA 2505887	AA	20040624	CA 2003-2505887	20031203
AU 2003286315	A1	20040630	AU 2003-286315	20031203

EP 1572662 A1 20050914 EP 2003-777058 20031203
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003017096 A 20051025 BR 2003-17096 20031203
 JP 2006514942 T2 20060518 JP 2004-558286 20031203
 PRIORITY APPLN. INFO.: US 2002-432911P P 20021212
 WO 2003-IB5835 W 20031203
 OTHER SOURCE(S): MARPAT 141:54345
 GI




I

AB Title compds. [I; X = C and Y = N, or X = N and Y = C; R1 = H, alkyl, halo, cyano; R2, R3 = (CH2)nAr; m, n = 0-2; p = 0-3; Ar = (substituted) aryl, heteroaryl; L = CO, CR4OR5; R4 = H, alkyl; R5 = H, alkyl; R5R8, R5R9 = CH2CH2, CH2CO; R6, R7 = H, alkyl; R6R7 = atoms to form a (partially) saturated carbocyclic ring; R8, R9 = H, alkyl, CO(CH2)mR10, SO2(CH2)nR10, (CH2)pR10; R8R9 = atoms to form a 4-8 membered (partially) saturated ring; R10 = (substituted) alkyl, (partially) saturated cycloalkyl, aryl, heteroaryl, heterocyclyl; dotted lines = bonds for form an aromatic ring], were prepared for treatment of obesity, alcoholism, or tobacco abuse (no data). Thus, 2-(benzylisopropylamino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]ethanone hydrochloride was stirred with NaBH4 in EtOH to give 2-(benzylisopropylamino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]ethanol.

IT 709033-30-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound; preparation of pyrazoles and imidazoles as cannabinoid receptor antagonists).

CB1 709033-30-7 HCAPLUS

RN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-
 CN α-[[1-(1-methylethyl)(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)



Andrew Freistein 10/702,149


IT 709035-74-5P 709035-75-6P 709035-76-7P
709035-84-7P 709035-95-0P 709035-97-2P
709036-04-4P 709036-12-4P 709036-26-0P
709036-35-1P 709036-38-4P 709036-39-5P
709036-47-5P 709036-49-7P 709036-50-0P
709036-53-3P 709036-54-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor
antagonists)

RN 709035-74-5 HCAPLUS


CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-
 α -[[(1-methylethyl) (phenylmethyl) amino]methyl]-, hydrochloride (9CI)
(CA INDEX NAME)



● x HCl


RN 709035-75-6 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)- α -[[(2-
hydroxyethyl) (phenylmethyl) amino]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 709035-76-7 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-
 α -[[(phenylmethyl) amino]methyl]-, hydrochloride (9CI) (CA INDEX
NAME)




● x HCl

RN 709035-84-7 HCAPLUS
 CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)- α -
 [(ethyl-1,3,4-thiadiazol-2-ylamino)methyl]-4-methyl- (9CI) (CA INDEX
 NAME)




RN 709035-95-0 HCAPLUS
 CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-
 α -[methyl[(1-methyl-1H-pyrazol-4-yl)methyl]amino]methyl]- (9CI)
 (CA INDEX NAME)



RN 709035-97-2 HCAPLUS


Andrew Freistein 10/702,149

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-
 α -[methyl(2-pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 709036-04-4 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-
 α -[1-methyl-1-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 709036-12-4 HCAPLUS

CN 1H-Pyrazole-3-methanol, α -[[bicyclo[2.2.1]hept-2-yl(phenylmethyl)amino]methyl]-1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 709036-26-0 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-
 α -[methyl[[1-(phenylmethyl)-3-pyrrolidinyl]methyl]amino]methyl]-


Andrew Freistein 10/702,149

(9CI) (CA INDEX NAME)




RN 709036-35-1 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)- α -[[[2-(hydroxymethyl)cyclohexyl](phenylmethyl)amino]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 709036-38-4 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)- α -[[[(2,6-dichlorophenyl)methyl](3-hydroxypropyl)amino]methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 709036-39-5 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)- α -[[[2-(hydroxycyclobutyl)(phenylmethyl)amino]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Andrew Freistein 10/702,149

NAME)




RN 709036-47-5 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-
 α -[[methyl(4-pyridinylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 709036-49-7 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-
 α -[[methyl(tetrahydro-1,1-dioxido-3-thienyl)amino]methyl]- (9CI)
(CA INDEX NAME)




RN 709036-50-0 HCAPLUS

CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)- α -[[[2-
hydroxy-1-methyl-2-phenylethyl)methylamino]methyl]-4-methyl- (9CI) (CA
INDEX NAME)




RN 709036-53-3 HCAPLUS

CN 1H-Pyrazole-3-ethanamine, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-β-methoxy-4-methyl-N-(1-methylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 709036-54-4 HCAPLUS


CN 1H-Pyrazole-3-methanol, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-α,4-dimethyl-α-[[1-(methylethyl)(phenylmethyl)amino]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:147866 HCAPLUS
DOCUMENT NUMBER: 78:147866

Andrew Freistein 10/702,149

TITLE: New method of synthesis of pyrazolo[4,3-c]pyridines
AUTHOR(S): Bourzat, J. D.; Marquet, J. P.; Civier, A.; Bisagni, E.
CORPORATE SOURCE: Lab. Synth. Org. Ford. Curie, Univ. Paris-Sud, Orsay, Fr.
SOURCE: Tetrahedron (1973), 29(2), 441-7
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 78:147866
GI For diagram(s), see printed CA Issue.
AB 2,4-Disubstituted pyrazolo-[4,3-c]pyridines (I, R = Me, CH₂Ph, R₁, H, SH, NHCH₂Ph, pyrrolidino) were prepared from 1-substituted 3-formly-4-(ethoxycarbonyl)pyrazoles by nitromethylation, reduction, cyclization, dehydration, chlorination, and substitution of the Cl in I (R = Me, Ph, R₁ = Cl). Similarly 1-substituted 5-formyl-4-(ethoxycarbonyl)pyrazoles gave the 1,4-disubstituted analogs (II, R = Ph, CH₂Ph, R₁ = H, SH, NHCH₂Ph, piperidino).
IT 41372-84-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41372-84-3 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-(1-hydroxy-2-nitroethyl)-1-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	28.08	195.23
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

STN INTERNATIONAL LOGOFF AT 16:32:06 ON 18 OCT 2006

10/23/2006

Page 18

Andrew Freistein 10/702,149